We are in the regulatory process to get an indication for the treatment of heart failure in both type 2 and non-type 2 diabetic patients, and this serves as just the start of the scientific investment that we have made with dapagliflozin, said Kiersten Combs, BS, US vice president of Cardiovascular Metabolism at AstraZeneca.
We are in the regulatory process to get an indication for the treatment of heart failure in both type 2 and non-type 2 diabetic patients, and this serves as just the start of the scientific investment that we have made with dapagliflozin, said Kiersten Combs, BS, U.S. vice president of Cardiovascular Metabolism at AstraZeneca.
Transcript
The FDA expanded the label for dapagliflozin in October to reduce heart failure in groups of patients with type 2 diabetes and cardiovascular disease. What will be the next indication that AstraZeneca will seek for dapagliflozin?
Based off the DAPA-HF data, we are in the regulatory process to get an indication for the treatment of heart failure in both type 2 and non-type 2 diabetic patients; but beyond that, that's just the beginning. We also are studying FARXIGA [dapagliflozin] in CKD patients, as well as, later on we have a study going on in HFpEF [heart failure with preserved ejection fraction] in heart failure also. So, really what you've seen with the label update that we had last month, what you're seeing with the data that's being presented with DAPA-HF, is just the start of the scientific investment that we've made with FARXIGA.
The early data also showed that the heart failure benefit increased for patients who are obese. Is this a group that should receive consideration in a future label expansion?
We're in the process, and some of the data that we're presenting here at AHA 2019 is looking at different patient characteristics, whether it be obesity or age, and also looking at the time in which you could see impact—a positive clinical impact in patients with heart failure. All of these data will be part of what we take forward and discuss with the FDA around future labels.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More